💰 Old Money’s Favorite: The Smart Accumulation Happening in $BDX 🏦📈

🏦 Institutional Money Is Quietly Loading Up On $BDX

📈 Despite Becton, Dickinson & Company ($BDX) lagging behind the broader market this year (-15.3% YTD vs $SPX +16.5%), the big money seems to see long-term value here. We’re seeing heavy institutional buying near the $160 zone, signaling accumulation before a potential major move higher.

🔸 With a market cap of $54.2B, BD is a global leader in medical technology, serving hospitals and research labs through its BD Medical, BD Life Sciences, and BD Interventional divisions.

🔸 Q4 earnings showed 8.3% YoY revenue growth and an EPS beat ($3.96 vs $3.81 last year), reflecting strong execution.

🔸 Forward guidance for 2026: EPS projected between $14.75–$15.05.

🔸 Analysts remain bullish: 6 Strong Buys, 1 Moderate Buy, and 9 Holds — with a mean target of $210.46 and a Street-high of $285, implying nearly 50% upside potential.

💡 Based on our institutional analysis, we expect accumulation to continue toward $220, where short-term profit taking may occur — but ultimately, price could break past previous highs as long-term holders position for future strength.

This is one of those “old money” stocks institutions love to hold quietly before the big run.